Drug ID:Drug31
Drug Name:Niclosamide
CID:4477
DrugBank ID:DB06803
Modality:Small Molecule
Groups:approved
US Approved:NO
Other Approved:YES
Identifier: NCT03521232
Molecular Formula:C13H8Cl2N2O4
Molecular Weight:327.12 g/mol
Isomeric SMILES:C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O
Synonyms:niclosamide; 50-65-7; Bayluscid; Phenasal; Cestocid; Devermin; Devermine; Helmiantin; Mansonil; Radeverm
Phase 0: 0
Phase 1: 9
Phase 2: 14
Phase 3: 5
Phase 4: 2
Description:Niclosamide is used for the treatment of most tapeworm infections. Helminths (worms) are multicellular organisms that infect very large numbers of humans and cause a broad range of diseases. Over 1 billion people are infected with intestinal nematodes, and many millions are infected with filarial nematodes, flukes, and tapeworms. They are an even greater problem in domestic animals. Drug32

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt287 4477 Niclosamide 1489680 ORF1ab Severe acute respiratory syndrome-related coronavirus 15974598 None
dt288 4477 Niclosamide 1489680 ORF1ab Severe acute respiratory syndrome-related coronavirus 34798775 None
dt289 4477 Niclosamide 196 AHR Homo sapiens (human) 23611293 None
dt290 4477 Niclosamide 1544 CYP1A2 Homo sapiens (human) 23611293 None
dt291 4477 Niclosamide 8856 NR1I2 Homo sapiens (human) 23611293 None
dt292 4477 Niclosamide 5465 PPARA Homo sapiens (human) 23611293 None
dt293 4477 Niclosamide 4799 NFX1 Homo sapiens (human) 23611293 None
dt294 4477 Niclosamide 1594 CYP27B1 Homo sapiens (human) 23611293 None
dt295 4477 Niclosamide 5451 POU2F1 Homo sapiens (human) 23611293 None

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT03521232 A Study of Niclosamide Enemas in Subjects With Active Ulcerative Proctitis or Ulcerative Proctosigmoiditis PHASE1|PHASE2 TERMINATED Entero Therapeutics Ulcerative Colitis|Ulcerative Proctitis|Ulcerativ… DRUG: Niclosamide Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
No data available

Niclosamide Enema for Active Distal Ulcerative Colitis: A Phase 1, Open-Label S…

PMID: 37478412
Year: 2024
Relationship Type: Treatment Score: 6.5

BACKGROUND: Oral and rectal formulations of 5-aminosalicylic acid are the first-line therapy for mild-to-moderate, distal ulcerative colitis (UC), bu…

View Details